Please use this identifier to cite or link to this item:
Title: Response to sequential treatment with prednisolone and vigabatrin in infantile spasms.
Austin Authors: Dzau, Winston;Cheng, Sally;Snell, Penny;Fahey, Michael;Scheffer, Ingrid E ;Harvey, A Simon;Howell, Katherine B
Affiliation: The Florey Institute of Neuroscience and Mental Health
Department of Neurology, The Royal Children's Hospital, Melbourne, Victoria, Australia
Neuroscience Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
Department of Paediatrics, Monash University, Melbourne, Victoria, Australia
Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia
Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
Issue Date: 24-Aug-2022 2022
Publication information: Journal of Paediatrics and Child Health 2022; 58(12)
Abstract: To report response to first treatment in infants with infantile spasms (IS), including incremental benefit of prednisolone 60 mg/day and vigabatrin following prednisolone 40 mg/day failure in infants commenced on the United Kingdom Infantile Spasms Study (UKISS) treatment sequence. In this retrospective analysis, we compared effectiveness of prednisolone, vigabatrin and nonstandard treatments as first treatment for IS. In infants who commenced the UKISS treatment sequence, we evaluated response to each step. Primary outcome was spasm cessation after 42 days. Secondary outcomes were severe side effects and spasm relapse after 42 days. Treatment response data were available for 151 infants. First treatment was prednisolone in 99 infants, vigabatrin in 18 and nonstandard treatment in 34. The rate of spasm cessation with first treatment was significantly higher with prednisolone (62/99, 63%) than vigabatrin (5/18, 28%, P = 0.01) or nonstandard treatment (2/34, 5.9%, P < 0.01). Of 112 infants who commenced the UKISS treatment sequence, 71/112 (63%) responded to prednisolone 40 mg/day. Among non-responders, 12/29 (41%) subsequently responded to prednisolone 60 mg/day, and 10/22 (45%) to vigabatrin. Severe side effects and spasm relapse were not significantly different between each treatment. We confirm higher rates of spasm cessation with initial treatment with prednisolone than vigabatrin and nonstandard therapy. Non-use of prednisolone as first treatment in over one third of infants highlights a concerning treatment gap. The UKISS treatment sequence has high overall treatment response (total 93/112; 83%), with similar benefit of subsequent prednisolone 60 mg/day and vigabatrin in prednisolone 40 mg/day non-responders.
DOI: 10.1111/jpc.16181
Journal: Journal of Paediatrics and Child Health
PubMed URL: 36054157
Type: Journal Article
Subjects: infantile spasms
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 9, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.